CareDx, Inc. (CDNA)
CareDx, Inc. (CDNA) is a molecular diagnostics company specializing in transplantation testing and monitoring. It develops and commercializes proprietary diagnostic products to improve graft survival and patient outcomes for organ transplant recipients. The company's offerings include assays for immune system monitoring and early detection of organ rejection, primarily serving the transplant community.
Company News
Johnson Fistel, a law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. for potential breaches of fiduciary duties and violations of federal securities laws. The investigation is related to CareDx's issuance of false and misleading public statements regarding its compliance with healthcare laws and revenue growth, which led to a significant drop in the company's stock price.
The article analyzes the recent analyst ratings and price targets for CareDx, a precision medicine company focused on transplant patients. It highlights the company's financial performance, including revenue decline, strong profitability, and high debt levels.
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The company's diagnostic tests may obtain better coverage from the Centers for Medicare & Medicaid Services.